Rua Bioscience (NZE:RUA) will import, distribute, and sell PharmAla Biotech's pharmaceutical-grade LaNeo MDMA in New Zealand under a new distribution and license deal between the companies, according to a Friday filing with the New Zealand bourse.

MDMA is a psychoactive compound often used recreationally as ecstasy. In a medical setting, it is administered as an adjunct to psychotherapy for conditions including post-traumatic stress disorder.

Under the deal, the first shipment of LaNeo MDMA will be supplied on a consignment basis, enabling Rua to enter the market with minimal upfront capital, the company said.